REAL-WORLD ANALYSIS ON THERAPEUTIC PATTERN AND ECONOMIC BURDEN OF ANDROGEN-RECEPTOR SIGNALING INHIBITORS (ARSI) AND TAXANE- BASED CHEMOTHERAPY TREATED METASTATIC CASTRATIONRESISTANT PROSTATE CANCER PATIENTS IN ITALY

被引：0
|
作者：
Dovizio, M. [1 ]
Mazzoni, S. [1 ]
Nappi, C. [1 ]
Saragoni, S. [1 ]
Degli Esposti, L. [1 ]
机构：
[1] CliCon Srl Societa Benefit Hlth, Econ & Outcomes Res, Bologna, BO, Italy
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PT36
引用
收藏
页码：S540 / S540
页数：1
相关论文
共 21 条
  • [1] Real-world analysis of the economic and therapeutic burden in advanced breast cancer patients in Italy
    Palladino, Simona
    Perrone, Valentina
    Giacomini, Elisa
    Sangiorgi, Diego
    Premoli, Eleonora
    Valsecchi, Diletta
    Degli Esposti, Luca
    Suter, Matteo Basilio
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2023, 23 (09) : 1041 - 1048
  • [2] Real-World Analysis on the Characteristics, Therapeutic Paths and Economic Burden for Patients Treated for Glaucoma in Italy
    Perrone, Valentina
    Formica, Dario
    Piergentili, Benedetta
    Rossetti, Luca
    Degli Esposti, Luca
    HEALTHCARE, 2023, 11 (05)
  • [3] Characteristics of long-term responder (LTR) patients (pts) treated with androgen-receptor signaling inhibitors (ARSI) as a first-line treatment for metastatic castration-resistant prostate cancer (mCRPC): Real-world evidence from four high-volume institutions.
    Caffo, Orazio
    Buttigliero, Consuelo
    Cattrini, Carlo
    Bimbatti, Davide
    Cani, Massimiliano
    Cavasin, Nicolo
    Crespi, Veronica
    Farinea, Giovanni
    Kadrija, Dzenete
    Kinspergher, Stefania
    Lai, Eleonora
    Maines, Francesca
    Mennitto, Alessia
    Veccia, Antonello
    Pappagallo, Giovanni L.
    Maruzzo, Marco
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [4] Real-world clinical outcomes and economic burden of early discontinuation of taxane therapy among patients with metastatic castration-resistant prostate cancer
    Patel, Jeetvan
    Nguyen, Jennifer
    Bollu, Vamsi
    Kang, Barinder
    Sawhney, Amrita
    Byrne, Clare
    Tang, Jackson
    Gorritz, Magdaliz
    Chen, Chi-Chang
    Shore, Neal D.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] Docetaxel Versus Androgen-Receptor Signaling Inhibitors (ARSI) as Second-Line Therapy After Failure of First-Line Alternative ARSI for the Elderly ≥ 75 Years Old With Metastatic Castration-Resistant Prostate Cancer (mCRPC): A SPARTACUSS-Meet-URO 26 Real-World Study
    Patrikidou, Anna
    Saieva, Calogero
    Lee-Ying, Richard
    Nuzzo, Pier Vitale
    El Zarif, Talal
    McClure, Heather
    Davidsohn, Matthew
    Eid, Marc
    Spinelli, Gian Paolo
    Catalano, Fabio
    Cremante, Malvina
    Fotia, Giuseppe
    Rossetti, Sabrina
    Valenca, Loana
    Vauchier, Charles
    Ottanelli, Carlotta
    Andrade, Livia
    Gennusa, Vincenzo
    Mestre, Ricardo Pereira
    Fornarini, Giuseppe
    Pignata, Sandro
    Procopio, Giuseppe
    Santini, Daniele
    Ravi, Praful
    Sweeney, Christopher
    De Giorgi, Ugo
    Fizazi, Karim
    Russo, Antonio
    Francini, Edoardo
    CLINICAL GENITOURINARY CANCER, 2024, 22 (06)
  • [6] A real-world observational study characterizing patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) treated with or without androgen receptor pathway inhibitors (ARPIs).
    O'Sullivan, Dylan E.
    Boyne, Devon J.
    Brenner, Darren R.
    Shokar, Simran
    Cheung, Winson Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 59 - 59
  • [7] Real-world outcomes in patients with metastatic castration-resistant prostate cancer beyond progression after upfront androgen receptor signaling inhibitor
    Yamamoto, Yutaka
    Fujimoto, Saizo
    Hashimoto, Mamoru
    Minami, Takafumi
    Fukuokaya, Wataru
    Yanagisawa, Takafumi
    Saruta, Masanobu
    Takahara, Kiyoshi
    Nishimura, Kazuki
    Tsujino, Takuya
    Nakamori, Yuta
    Hashimoto, Takeshi
    Kimura, Takahiro
    Shiroki, Ryoichi
    Azuma, Haruhito
    Ohno, Yoshio
    Fujita, Kazutoshi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, : 1946 - 1958
  • [8] Real-world incidence and burden of adverse events among non-metastatic prostate cancer patients treated with secondary hormonal therapies following androgen deprivation therapy
    Shah, Anuj
    Shah, Ruchit
    Kebede, Nehemiah
    Mohamed, Ateesha
    Botteman, Marc
    Waldeck, Reg
    Hussain, Arif
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (04) : 330 - 346
  • [9] Glucocorticoid receptor (GR) expression in circulating tumor cells (CTCs) to prognosticate overall survival (OS) for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with androgen receptor signaling inhibitors (ARSi).
    Wise, David
    Kelvin, James
    Graf, Ryon
    Schreiber, Nicole A.
    McLaughlin, Brigit
    Fernandez, Luisa
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [10] Predictive biomarkers of sensitivity to androgen receptor signaling (ARS) and taxane-based chemotherapy in circulating tumor cells (CTCs) of patients (pts) with metastatic castration resistant prostate cancer (mCRPC).
    Scher, Howard I.
    Louw, Jessica
    Jendrisak, Adam
    Bambury, Richard Martin
    Danila, Daniel Costin
    Rathkopf, Dana E.
    Arslan, Zaina
    Schreiber, Nicole A.
    Lu, David
    Krupa, Rachel
    Marrinucci, Dena
    Landers, Mark
    Dittamore, Ryan Vance
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
123